Dr. Céline Mirjolet is a radiobiologist with in-depth knowledge of the impact of radiotherapy fractionation on the radiation-induced immune response and on the effectiveness of the radiotherapy and immunotherapy combination. She obtained a doctorate in radiobiology at the anti-cancer center of Nancy (France). She then moved to Brussels at the University of Belgium to study epigenetic mechanisms in transcriptional activity and cancer. For ten years, she has been working in the radiotherapy department of the Dijon cancer center in close collaboration with clinicians and physicists to develop translational research projects on the combination of immunotherapy and radiotherapy. She leads the preclinical research team in radiotherapy and radiobiology and her programs focus on the validation of preclinical concepts leading to the design of clinical trials.